Login to Your Account

arGEN-X Expands Shire Deal; Starts Phase Ib Cancer Trial

By Nuala Moran
Staff Writer

Wednesday, January 9, 2013
arGEN-X BV is making strides in the commercialization of its antibody platform, announcing an extension of its existing collaboration with Shire plc in rare diseases and at the same time advancing the lead in-house program into a Phase Ib first-in-man trial.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription